United States Health

Johnson & Johnson (NYSE:JNJ) reported 35% combined fistula remission at Week 48 with TREMFYA in its Phase 3 FUZION Crohn's disease trial.

Merck (NYSE:MRK) agreed to acquire Silence Therapeutics (NASDAQ:SLN) for $20 per ADS, valuing its equity at approximately $1.3 billion.

Cytokinetics (NASDAQ:CYTK) received Health Canada approval for MYQORZO to treat adults with NYHA class II–III symptomatic obstructive hypertrophic cardiomyopathy, supported by 24-week trial results.

EyePoint (NASDAQ:EYPT) announced plans to reduce its workforce by approximately 53%, targeting $30 million in annual savings following disappointing Phase 3 results.

Biodesix (NASDAQ:BDSX) announced plans to develop an AI-powered lung nodule risk test with Vanderbilt University and Vanderbilt Health, targeting commercial availability in 2028.

BeOne Medicines (NASDAQ:ONC) announced presentations covering four investigational cancer therapies and seven TEVIMBRA abstracts at ESMO 2026 in Madrid.

IDEAYA Biosciences (NASDAQ:IDYA) reported a 57% eye preservation rate in its OptimUM-09 trial, alongside updated darovasertib findings from two metastatic uveal melanoma studies.

Takeda (NYSE:TAK) reported a 67% lower relative risk of ulcerative colitis complications with ENTYVIO-based treatment targeting disease clearance rather than symptomatic remission alone.

Eli Lilly (NYSE:LLY) reported that Omvoh met its Phase 3 SHINE-2 primary endpoint, with 50% of 52 pediatric responders achieving clinical remission at Week 52.

AbbVie (NYSE:ABBV) reported a 40.5% endoscopic remission rate at Week 24 for investigational ABBV-466 in its 300-patient Phase 2a TARGET-CD Crohn's disease trial.

Telix Pharmaceuticals (NASDAQ:TLX) announced a collaboration with Ekalia to develop U.S. production of astatine-211, starting with one cyclotron installation near Philadelphia.

Oculis (NASDAQ:OCS) completed randomization of 176 patients in its PREDICT-1 registrational trial of Licaminlimab, advancing its development program for dry eye disease.